Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SARomics Biostructures and Red Glead Discovery Enters into Drug Discovery Collaboration

Published: Thursday, October 25, 2012
Last Updated: Thursday, October 25, 2012
Bookmark and Share
The companies will perform a joint collaborative project with the goal of developing novel lead compounds against epigenetic pathway targets.

SARomics Biostructures and Red Glead Discovery have announced that they have entered into a drug discovery collaboration.

Targeting proteins involved in epigenetic mechanisms (the cellular processes associated with the modification of chromatin) have emerged as an important new therapeutic opportunity for treating cancer, diabetes, inflammatory diseases and more.

By merging the unique and highly complementary capabilities of the two companies, an efficient and versatile fragment-based lead discovery (FBLD) platform is enabled.

The advanced structural biology platform and expertise contributed by SARomics Biostructures are combined with the bioassay technology and medicinal chemistry skills of Red Glead Discovery.

The scientific excellence of the alliance is reflected by the track record of Red Glead Discovery for delivery of lead compounds and the established platform for structure-based drug design implemented by SARomics Biostructures.

For the project, the companies will share costs and the generated intellectual property rights.

Project progress and the discovery of lead compounds will be effectuated by utilization of FBLD, which is a powerful alternative to costly and resource-intensive high-throughput screening (HTS) campaigns.

At this stage of the project, the collaboration will be run without external financing.

Björn Walse, CEO of SARomics Biostructures, said “We are excited about the opportunity to work with Red Glead Discovery on this frontline project that clearly leverages the competitiveness of both companies. We see this initiative as highly complementary to SARomics’ other collaborations, such as those within KINOMED, which focus on protein kinase off-the-shelf crystal structures and fragment complexes.”

Johan Evenäs, CEO of Red Glead Discovery, added “I am convinced that we have a perfect match of competences and experiences enabling a project that would have been difficult for either company alone at this stage. We expect the close proximity of our two companies within the Lund Life Science Incubator at Medicon Village to further facilitate effective collaboration.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A New EU-Funded Industry-Academia Drug Discovery Partnership Targets Challenging Kinases
Industry and academia join to create the Translational Kinase Tumor Inhibitor Discovery Consortium.
Wednesday, April 10, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Sensor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!